The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules
- PMID: 9278300
The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules
Abstract
Cells were treated with two proteolytic inhibitors, N-acetyl-leucyl-leucyl-norleucinal and lactacystin, the latter reported to be a specific inhibitor for the proteasome. Both inhibitors retarded the maturation of endo-H-resistant forms of murine and human class I molecules from their endo-H-sensitive precursors in cell lines with functional TAP proteins. HLA-A2 maturation readily occurs in TAP-deficient T2 cells, and it has been shown that the peptides associated with A2 are derived from the leader segment of proteins in the secretory pathway. This maturation is inhibited by N-acetyl-leucyl-leucyl-norleucinal but not lactacystin, indicating that the proteasome is not required for the generation of HLA-A2 binding peptides in these cells. The murine class Ib molecule Qa-1b presents a leader peptide derived from D-end class I molecules to alloreactive CTL. Since this presentation is dependent on the expression of TAP proteins, we determined if this requirement reflects a need for the proteasome to process this peptide. We found that lactacystin did not inhibit the maturation of endo-H-resistant forms of Qa-1b that are dependent on this leader peptide for its maturation, nor did it inhibit the expression of this peptide-Qa-1b complex in a functional assay. Thus, unlike conventional cytosolic peptides, leader peptides (regardless of whether they are dependent on TAP for their presentation) do not require the proteasome for processing.
Similar articles
-
Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol.J Immunol. 1998 Jul 1;161(1):112-21. J Immunol. 1998. PMID: 9647214
-
Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope.Int J Cancer. 2000 Nov 1;88(3):432-8. Int J Cancer. 2000. PMID: 11054673
-
Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation.J Immunol. 2000 May 15;164(10):5070-7. doi: 10.4049/jimmunol.164.10.5070. J Immunol. 2000. PMID: 10799863
-
Processing and delivery of peptides presented by MHC class I molecules.Curr Opin Immunol. 1996 Feb;8(1):59-67. doi: 10.1016/s0952-7915(96)80106-3. Curr Opin Immunol. 1996. PMID: 8729447 Review.
-
Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases.Mol Immunol. 2002 Oct;39(3-4):203-15. doi: 10.1016/s0161-5890(02)00102-5. Mol Immunol. 2002. PMID: 12200051 Review.
Cited by
-
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.Mol Ther. 2010 Jan;18(1):135-42. doi: 10.1038/mt.2009.257. Epub 2009 Nov 10. Mol Ther. 2010. PMID: 19904235 Free PMC article.
-
Physical association of the K3 protein of gamma-2 herpesvirus 68 with major histocompatibility complex class I molecules with impaired peptide and beta(2)-microglobulin assembly.J Virol. 2002 Mar;76(6):2796-803. doi: 10.1128/jvi.76.6.2796-2803.2002. J Virol. 2002. PMID: 11861847 Free PMC article.
-
Intrasequence GFP in class I MHC molecules, a rigid probe for fluorescence anisotropy measurements of the membrane environment.Biophys J. 2003 Jun;84(6):4078-86. doi: 10.1016/S0006-3495(03)75133-9. Biophys J. 2003. PMID: 12770911 Free PMC article.
-
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.Blood. 2008 Feb 1;111(3):1309-17. doi: 10.1182/blood-2007-03-078535. Epub 2007 Oct 18. Blood. 2008. PMID: 17947507 Free PMC article.
-
Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.Oncotarget. 2015 Sep 29;6(29):26982-94. doi: 10.18632/oncotarget.4831. Oncotarget. 2015. PMID: 26323098 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials
Miscellaneous